Marked impact of P-glycoprotein on the absorption of TAK-427 in rats

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 6, 2008, Pages 311-323

  Takeuchi, Toshiyuki ^a   Nonaka, Masami ^a   Yoshitomi, Sumie ^a   Higuchi, Tomoaki ^a   Ebihara, Takuya ^a   Maeshiba, Yoshihiro ^a   Kawase, Masahiro ^a   Asahi, Satoru ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

ABCB1); Absorption; Bioavailability; P glycoprotein (P gp; Rat; TAK 427

Indexed keywords

2 [6 [[3 [4 (DIPHENYLMETHOXY)PIPERIDINO]PROPYL]AMINO]IMIDAZO[1,2 B]PYRIDAZIN 2 YL] 2 METHYLPROPIONIC ACID DIHYDRATE; ERYTHROMYCIN; GLYCOPROTEIN P; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; MULTIDRUG RESISTANCE PROTEIN 1B; PROPIONIC ACID DERIVATIVE; QUINIDINE; TAK 427; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; GASTROINTESTINAL TRACT; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; IMIDAZOLES; INTESTINE, SMALL; MALE; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PERMEABILITY; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 53349097917     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.609     Document Type: Article

References (27)

1. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469-497.
2. Tsuji A. Biopharmaceutical studies on molecular mechanisms of membrane transport. Yakugaku Zasshi 2002; 122: 1037-1058.
3. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-2035.
4. Toyobuku H, Tamai I, Ueno K, Tsuji A. Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J Pharm Sci 2003; 92: 2249-2259.
5. Cao X, Yu LX, Barbaciru C, et al. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol Pharm 2005; 2: 329-340.
6. Fukuda S, Midoro K, Kamei T, et al. Inhibition of allergic dermal inflammation by the novel imidazopyridazine derivative TAK-427 in a guinea pig experimental model of eczema. J Pharmacol Exp Ther 2002; 303: 1283-1290.
7. Tsuji A. Transporter-mediated drug interactions. Drug Metab Pharmacokinet 2002; 17: 253-274.
8. Tanayama S, Kobayashi T, Kanai Y. Metabolism of 3-(2′,4′,5′-triethoxybenzoyl) propionic acid, a new biliary smooth muscle relaxant with choleretic activity. I. Disposition after a single administration in rats and dogs. Xenobiotica 1978; 8: 365-375.
9. Emi Y, Tsunashima D, Ogawara K, Higaki K, Kimura T. Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine. J Pharm Sci 1998; 87: 295-299.
10. 1. Pharm Res 2006; 23: 1460-1472.
11. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for micro-computer. J Pharmacobiodyn 1981; 4: 879-885.
12. Adachi Y, Suzuki H, Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 2001; 18: 1660-1668.
13. Kohno Y, Yoshida H, Suwa T, Suga T. Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. Antimicrob Agents Chemother 1989; 33: 751-756.
14. Remmel RP, Amoh K, Abdel-Monem MM. The disposition and pharmacokinetics of ketoconazole in the rat. Drug Metab Dispos 1987; 15: 735-739.
15. Otto U, Paalzow L. Effect of stress on the pharmacokinetics of sodium salicylate and quinidine sulphate in rats. Acta Pharmacol Toxicol 1975; 36: 415-426.
16. Polli JW, Wring SA, Humphreys JE, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299: 620-628.
17. Rautio J, Humphreys JE, Webster LO, et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006; 34: 786-792.
18. Goh LB, Spears KJ, Yao D, et al. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 2002; 64: 1569-1578.
19. 1 cells. Am J Physiol 1998; 275: C1573-C1579.
20. Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci 2006; 95: 2673-2683.
21. Taylor JC, Ferry DR, Higgins CF, Callaghan R. The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. Br J Cancer 1999; 81: 783-789.
22. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-168.
23. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD. Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 2002; 30: 838-844.
24. Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos 2006; 34: 793-799.
25. Valenzuela B, Nacher A, Ruiz-Carretero P, Martin-Villodre A, Lopez-Carballo G, Barettino D. Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J Pharm Sci 2004; 93: 1641-1648.
26. Mottino AD, Hoffman T, Jennes L, Vore M. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 2000; 293: 717-723.
27. He YL, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci 1998; 87: 626-633.